399 related articles for article (PubMed ID: 29455646)
1. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
Wu S; Fu L
Mol Cancer; 2018 Feb; 17(1):25. PubMed ID: 29455646
[TBL] [Abstract][Full Text] [Related]
2. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
4. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
[TBL] [Abstract][Full Text] [Related]
5. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
7. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
[TBL] [Abstract][Full Text] [Related]
9. Reversing multidrug resistance by tyrosine kinase inhibitors.
He M; Wei MJ
Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
[TBL] [Abstract][Full Text] [Related]
11. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
Wang XK; Fu LW
Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
[TBL] [Abstract][Full Text] [Related]
12. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance.
Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B
Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575
[TBL] [Abstract][Full Text] [Related]
13. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
[TBL] [Abstract][Full Text] [Related]
14. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
15. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
17. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
18. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
19. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
20. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D; Staud F; Ceckova M
Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
